Isolation and characterization of broadly-neutralizing anti-HCMV-gB antibodies from human donors using a prefusion-stabilized HCMV gB variant
PLOS Pathogens · 2026
DOI: 10.1371/journal.ppat.1013950 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Maria K McClave und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Cytomegalovirus, Antibodies, Neutralizing, Viral Envelope Proteins, Antibodies, Viral. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Human cytomegalovirus (HCMV) poses a significant risk to immunocompromised individuals and is the leading cause of congenital birth defects worldwide. There is no cure or robust treatment options, although neutralizing antibodies (nAbs) derived from patient sera are being explored as prophylactics with limited success. Glycoprotein B (gB) is a viral membrane fusogen and a major target of the anti-HCMV humoral response in humans. Here, we engineered a soluble, prefusion-stabilized HCMV gB ectodomain variant and used it to isolate twelve new human monoclonal antibodies (mAbs). Seven of these mAbs strongly neutralized at least one strain of HCMV in vitro, whereas six mAbs neutralized both lab-adapted and minimally passaged clinical strains (were broadly neutralizing, bnAbs). All nAbs bound different epitopes within antigenic regions AD-4 or AD-5, and most targeted new sites. Despite being isolated using prefusion-stabilized HCMV gB variant, nAbs varied in their conformational specificity. Only one nAb preferentially bound the prefusion form, and most preferentially bound the intermediate form. The seven nAbs were separated into three classes based on their putative neutralization mechanisms, which were deduced from their conformational specificity, reactivity with gB on the cell surface, and epitope location. Our stabilized prefusion-gB construct provides a tool for isolating potent new nAbs, including prefusion-specific ones, and studying HCMV immunogenicity. Long term, these potent nAbs that arose during natural infections could be developed into potent prophylactics and therapeutics against HCMV diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, United States of America.
- Graduate Program in Molecular Microbiology, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States of America.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
- Faculty of Experimental Sciences, Department of Biotechnology, University of Francisco de Vitoria, Madrid, Spain.
- Graduate Program in Genetics, Molecular, and Cell Biology, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States of America.
- Department of Global Health, University of Washington, Seattle, Washington, United States of America.
ORCID-Profile: Ekaterina E Heldwein
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
- Howard Hughes Medical Institute
Zitieren
APA
McClave, M. K., Wan, Y. H., White, E. M., Gálvez Martínez, B., Karimian Shamsabadi, M., Aldridge, N., Poudel, B., Sperl, A. W., McGuire, A. T., & Heldwein, E. E. (2026). Isolation and characterization of broadly-neutralizing anti-HCMV-gB antibodies from human donors using a prefusion-stabilized HCMV gB variant. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013950
Vancouver
McClave MK, Wan YH, White EM, Gálvez Martínez B, Karimian Shamsabadi M, Aldridge N, et al. Isolation and characterization of broadly-neutralizing anti-HCMV-gB antibodies from human donors using a prefusion-stabilized HCMV gB variant. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1013950
BibTeX
@article{McClave2026,
author = {McClave, Maria K and Wan, Yu-Hsin and White, Ellen M and Gálvez Martínez, Beatriz and Karimian Shamsabadi, Mohammad and Aldridge, Nicholas and Poudel, Bibhav and Sperl, Adrian W and McGuire, Andrew T and Heldwein, Ekaterina E},
title = {Isolation and characterization of broadly-neutralizing anti-HCMV-gB antibodies from human donors using a prefusion-stabilized HCMV gB variant},
journal = {PLOS Pathogens},
year = {2026},
doi = {10.1371/journal.ppat.1013950}
}
EUVIMED